Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy has heralded a transformative era in the treatment of multiple myeloma (MM) following the first relapse. I Chimeric antigen receptor T-cell (CAR-T) therapy has heralded a transformative era in the treatment of multiple myeloma (MM) following the first relapse. I

This publication has 8 references indexed in Scilit: